ActiveHealth ™s patented technology, the CareEngine?® System, powers Active Disease ManagementSM and ActiveHealth ™s VBID program, which is known as Active Benefit DesignSM. The CareEngine creates a personal health profile for each individual using claims and other data, and compares the profile to the evidence-based literature. As part of this process, the CareEngine identifies the individuals whose clinical profile indicates they could most benefit from disease management nurse coaching, as well as the individuals who would most benefit from a medication included in the incentive program. Program medications were selected based on the large body of evidence-based medical literature documenting their cost effectiveness in the treatment of common chronic conditions.

The paper was Michael E. Chernew, professor in the Department of Health Care Policy at Harvard Medical School, Iver A. Juster, senior vice president for Informatics at ActiveHealth, Mayur Shah, formerly employed at ActiveHealth, Arnold Wegh, senior informatics analyst at ActiveHealth, Stephen Rosenberg, senior vice president for Outcomes Research at ActiveHealth, Michael C. Sokol, corporate medical director for Merck and Company, Kristine Yu-Isenberg, associate director in Regional Outcomes Research at Ortho-McNeil Janssen Scientific Affairs and A. Mark Fendrick, professor in the Division of General Medicine at the University of Michigan.

The current paper complements an earlier study published in Health Affairs by researchers from ActiveHealth, Harvard Medical School and the University of Michigan. That study showed that lowering co-pays for certain classes of drugs improves medication compliance. The study demonstrated that ActiveHealth ™s VBID incentive can be effective in increasing compliance with important medications and can complement ActiveHealth ™s disease management program.

Source: ActiveHealth Management